For informational purposes only — not investment advice

← Back to signals

BBIO

CONGRESS BUY

BridgeBio Pharma, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
7.1d↑+6.0%
as of 2026-10-30 · shares short vs 2026-09-30

Fund 13D/13G Filings (3)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Viking GlobalSC 13D/A−2.1M5.0%
-27.1% vs SPY
-24.3% abs
2026-07-10↗
Viking GlobalSC 13D/A—6.1%—2026-04-02↗
Viking GlobalSC 13D/A—6.8%—2026-02-17↗

Tracked Funds Holding (2)

FundManagerShares HeldPosition Value
Viking GlobalAndreas Halvorsen9.8M$644M
Point72Steve Cohen602K$40M

Quarter-end 13F positions for the tracked funds holding this stock.

Congressional Trading

MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Gilbert CisneroshouseCA31BUY$1,001 - $15,0002026-11-022026-11-10↗
Gilbert CisneroshouseCA31BUY$1,001 - $15,0002026-10-272026-11-10↗

Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jul 1, 2026.